Crescita Therapeutics Inc. (TSX:CTX)
Canada
· Delayed Price · Currency is CAD 0.450
-0.010 (-2.17%)
At close: Mar 6, 2026
Crescita Therapeutics Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 22.07 | 19.58 | 17.52 | 23.53 | 16.77 | 15.64 | Upgrade
|
| Revenue Growth (YoY) | 26.79% | 11.74% | -25.52% | 40.29% | 7.22% | -29.98% | Upgrade
|
| Cost of Revenue | 10.64 | 9.97 | 7.16 | 10.34 | 6.76 | 4.37 | Upgrade
|
| Gross Profit | 11.42 | 9.61 | 10.36 | 13.18 | 10.01 | 11.27 | Upgrade
|
| Selling, General & Admin | 10.18 | 10.68 | 10.12 | 10.57 | 9.5 | 7.85 | Upgrade
|
| Research & Development | 0.57 | 0.65 | 0.7 | 0.61 | 0.63 | 1.1 | Upgrade
|
| Operating Expenses | 12.2 | 12.7 | 12.32 | 12.65 | 11.51 | 10.44 | Upgrade
|
| Operating Income | -0.78 | -3.09 | -1.96 | 0.53 | -1.5 | 0.83 | Upgrade
|
| Interest Expense | -0.05 | -0.07 | -0.09 | -0.16 | -0.24 | -0.25 | Upgrade
|
| Interest & Investment Income | 0.4 | 0.5 | 0.51 | 0.26 | 0.18 | 0.29 | Upgrade
|
| Earnings From Equity Investments | -0.07 | -0.05 | 0.02 | -0.06 | 0.01 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 0.14 | -0.04 | 0.01 | -0.05 | -0.24 | 0.18 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.1 | - | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | 0.74 | -2.75 | -1.51 | 0.52 | -1.79 | 1.05 | Upgrade
|
| Merger & Restructuring Charges | -0.13 | -0.13 | - | - | - | - | Upgrade
|
| Asset Writedown | - | - | - | - | - | -1.92 | Upgrade
|
| Other Unusual Items | 0.11 | 0.11 | -0.02 | -0.12 | 0.78 | 1.39 | Upgrade
|
| Pretax Income | 0.44 | -2.76 | -1.53 | 0.4 | -1.01 | 0.52 | Upgrade
|
| Income Tax Expense | -0.01 | -0.01 | 0.46 | -0.46 | 0.1 | 0.48 | Upgrade
|
| Earnings From Continuing Operations | 0.46 | -2.75 | -1.99 | 0.86 | -1.11 | 0.04 | Upgrade
|
| Net Income | 0.46 | -2.75 | -1.99 | 0.86 | -1.11 | 0.04 | Upgrade
|
| Net Income to Common | 0.46 | -2.75 | -1.99 | 0.86 | -1.11 | 0.04 | Upgrade
|
| Net Income Growth | - | - | - | - | - | -98.00% | Upgrade
|
| Shares Outstanding (Basic) | 19 | 19 | 20 | 21 | 21 | 21 | Upgrade
|
| Shares Outstanding (Diluted) | 19 | 19 | 20 | 21 | 21 | 21 | Upgrade
|
| Shares Change (YoY) | -2.70% | -4.44% | -3.55% | 1.18% | -1.02% | -6.79% | Upgrade
|
| EPS (Basic) | 0.02 | -0.14 | -0.10 | 0.04 | -0.05 | 0.00 | Upgrade
|
| EPS (Diluted) | 0.02 | -0.14 | -0.10 | 0.04 | -0.05 | 0.00 | Upgrade
|
| EPS Growth | - | - | - | - | - | -97.96% | Upgrade
|
| Free Cash Flow | 0.62 | 0.63 | 1.94 | -1.25 | -1.94 | 5.55 | Upgrade
|
| Free Cash Flow Per Share | 0.03 | 0.03 | 0.10 | -0.06 | -0.09 | 0.27 | Upgrade
|
| Gross Margin | 51.77% | 49.07% | 59.15% | 56.03% | 59.72% | 72.08% | Upgrade
|
| Operating Margin | -3.54% | -15.77% | -11.16% | 2.25% | -8.92% | 5.33% | Upgrade
|
| Profit Margin | 2.07% | -14.04% | -11.33% | 3.66% | -6.59% | 0.24% | Upgrade
|
| Free Cash Flow Margin | 2.82% | 3.21% | 11.09% | -5.31% | -11.59% | 35.48% | Upgrade
|
| EBITDA | 0.25 | -2.15 | -0.86 | 1.61 | -0.48 | 2.02 | Upgrade
|
| EBITDA Margin | 1.13% | -10.96% | -4.89% | 6.86% | -2.86% | 12.91% | Upgrade
|
| D&A For EBITDA | 1.03 | 0.94 | 1.1 | 1.08 | 1.02 | 1.19 | Upgrade
|
| EBIT | -0.78 | -3.09 | -1.96 | 0.53 | -1.5 | 0.83 | Upgrade
|
| EBIT Margin | -3.54% | -15.77% | -11.16% | 2.25% | -8.92% | 5.33% | Upgrade
|
| Effective Tax Rate | - | - | - | - | - | 92.88% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.